 | • レポートコード：MRC2110B020 • 出版社/出版日：Persistence Market Research / 2021年9月30日 • レポート形態：英文、PDF、259ページ • 納品方法：Eメール • 産業分類：医療 |
| Individual User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Multi User | ￥1,124,800 (USD7,600) | ▷ お問い合わせ |
| Corporate User | ￥1,568,800 (USD10,600) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Persistence Market Research社の本調査レポートでは、過敏性腸症候群（IBS）治療の世界市場について調査し、エグゼクティブサマリー、市場概要、主要市場動向、市場背景、新型コロナウイルス感染症の危機分析、主要成功要因、価格分析・予測、薬剤種類別（繊維サプリメント、止瀉薬、抗コリン作用薬・鎮痙薬、抗うつ薬、抗生物質）分析、疾患別（便秘型過敏性腸症候群、下痢型過敏性腸症候群、便秘・下痢混合型過敏性腸症候群）分析、流通チャネル別（病院薬局、小売薬局、ドラッグストア、オンライン薬局・店舗、ハイパーマーケット・スーパーマーケット）分析、地域別分析、市場構造分析、競争分析、仮定、調査手法などを掲載しています。 ・エグゼクティブサマリー ・市場概要 ・主要市場動向 ・市場背景 ・新型コロナウイルス感染症の危機分析 ・主要成功要因 ・価格分析・予測 ・過敏性腸症候群（IBS）治療の世界市場規模：薬剤種類別（繊維サプリメント、止瀉薬、抗コリン作用薬・鎮痙薬、抗うつ薬、抗生物質） ・過敏性腸症候群（IBS）治療の世界市場規模：疾患別（便秘型過敏性腸症候群、下痢型過敏性腸症候群、便秘・下痢混合型過敏性腸症候群） ・過敏性腸症候群（IBS）治療の世界市場規模：流通チャネル別（病院薬局、小売薬局、ドラッグストア、オンライン薬局・店舗、ハイパーマーケット・スーパーマーケット） ・過敏性腸症候群（IBS）治療の世界市場規模：地域別 ・市場構造分析 ・競争分析 ・仮定 ・調査手法 |
Irritable Bowel Syndrome Treatment Market – Scope of Report
The latest publication by Persistence Market Research on the global irritable bowel syndrome treatment market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market.
The study offers detailed insights on current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2021-2031.
Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research’s study. This research study can support readers to know the demand for irritable bowel syndrome treatment products and the quantitative development opportunities during the study period.
The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the irritable bowel syndrome treatment market.
The insights and information presented in this Persistence Market Research study can be leveraged by shareholders in the Irritable Bowel Syndrome Treatment market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.
Market statistics, as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the irritable bowel syndrome treatment market, are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.
Key Market Segments
Persistence Market Research’s study on the irritable bowel syndrome treatment market offers information divided into four important segments – drug type, indication, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
[Drug Type]
Fiber Supplements
Anti-Diarrheal
Anticholinergic and Antispasmodic
Antidepressants
Antibiotics
Alosetron
Lubiprostone
Linaclotide
NHE3
[Indication]
Irritable Bowel Syndrome with Constipation
Irritable Bowel Syndrome with Diarrhea
Irritable Bowel Syndrome with Alternating Constipation and Diarrhea
[Distribution Channel]
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies and Stores
Hypermarkets and Supermarkets
[Region]
North America
Latin America
Europe
East Asia
South Asia and Pacific
MEA
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusion and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Method Innovation / Development Trends
4. Market Background
4.1. Macro-Economic Factors
4.1.1. Global GDP Growth Outlook
4.1.2. Global Pharmaceutical Outlook
4.1.3. Global Ageing Population Outlook
4.2. Forecast Factors – Relevance & Impact
4.2.1. Rising diagnostic rate of Irritable Bowel Syndrome
4.2.2. New product launches
4.2.3. Increasing healthcare spending per capita
4.2.4. Historic growth of manufactures
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Trends
4.3.4. Opportunity Analysis
5. COVID19 Crisis Analysis
5.1. Current COVID19 Probable Future Impact
5.2. Current GDP Projection and Probable Impact
5.3. COVID19 and Impact Analysis
5.3.1. Revenue by Drug Type
5.3.2. Revenue by Indication
5.3.3. Revenue by Distribution Channel
5.3.4. Revenue By Country
5.4. 2020 Market Scenario
5.5. Recovery Scenario – Short term, Midterm and Long Term Impact
6. Key Success Factors
6.1. Key Disease Epidemiology
6.2. Treatment Patterns and Adoption Analysis
6.3. Pipeline Analysis
6.4. Value Chain Analysis
6.5. Key Manufacturers Promotional Strategies
7. Global Irritable Bowel Syndrome Value (US$ Mn) Analysis 2016-2020 and Forecast, 2021-2031
7.1. Historical Market Value (US$ Mn) Analysis, 2016-2020
7.2. Current and Future Market Value (In Value or Size in US$ Mn) Projections, 2021-2031
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Irritable Bowel Syndrome Treatment Market Analysis 2016-2020 and Forecast 2021-2031, By Drug Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (In Value or Size in US$ Mn) Trend By Drug Type, 2016-2020
8.3. Current and Future Market Size (In Value or Size in US$ Mn) Trend Analysis and Forecast By Drug Type, 2021-2031
8.3.1. Fiber Supplements
8.3.2. Anti-Diarrheal
8.3.3. Anticholinergic and Antispasmodic
8.3.4. Antidepressant
8.3.5. Antibiotics
8.3.6. Alosetron
8.3.7. Lubiprostone
8.3.8. Linaclotide
8.3.9. NHE3
8.4. Market Attractiveness Analysis By Drug Type
9. Global Irritable Bowel Syndrome Treatment Market Analysis 2016-2020 and Forecast 2021-2031, By Indication
9.1. Introduction / Key Findings
9.2. Historical Market Size (In Value or Size in US$ Mn) Trend By Indication, 2016-2020
9.3. Current and Future Market Size (In Value or Size in US$ Mn) Trend Analysis and Forecast By Indication, 2021-2031
9.3.1. Irritable Bowel Syndrome with Constipation
9.3.2. Irritable Bowel Syndrome with Diarrhea
9.3.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhea
9.4. Market Attractiveness Analysis By Indication
10. Global Irritable Bowel Syndrome Treatment Market Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel
10.1. Introduction / Key Findings
10.2. Historical Market Size (In Value or Size in US$ Mn) Trend By Distribution Channel, 2016-2020
10.3. Current and Future Market Size (In Value or Size in US$ Mn) Trend Analysis and Forecast By Distribution Channel , 2021-2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Drug Stores
10.3.4. Online Pharmacies and Stores
10.3.5. Hypermarkets and Supermarkets
10.4. Market Attractiveness Analysis By Distribution Channel
11. Global Irritable Bowel Syndrome Treatment Market Analysis 2016-2020 and Forecast 2021-2031, by Region
11.1. Introduction
11.2. Historical Market Size (In Value or Size in US$ Mn) Analysis By Region, 2016 – 2020
11.3. Current Market Size (In Value or Size in US$ Mn) Analysis and Forecast By Region, 2021 – 2031
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. East Asia
11.3.5. South Asia and Pacific
11.3.6. Middle East and Africa (MEA)
11.4. Market Attractiveness Analysis By Region
12. North America Irritable Bowel Syndrome Treatment Market Analysis 2016-2020 and Forecast 2021-2031
12.1. Introduction
12.2. Historical Market Size (In Value or Size in US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
12.3. Current and Future Market Size (In Value or Size in US$ Mn) Trend Analysis Forecast By Market Taxonomy, 2021-2031
12.3.1. By Country
12.3.1.1. U.S.
12.3.1.2. Canada
12.3.2. By Drug Type
12.3.3. By Indication
12.3.4. By Distribution Channel
12.4. Market Attractiveness Analysis
12.5. Key Market Participants – Intensity Mapping
12.6. Drivers and Restraints – Impact Analysis
13. Latin America Irritable Bowel Syndrome Treatment Market Analysis 2016-2020 and Forecast 2021-2031
13.1. Introduction
13.2. Historical Market Size (In Value or Size in US$ Mn) Trend Analysis By Market Taxonomy, 2016 – 2020
13.3. Current and Future Market Size (In Value or Size in US$ Mn) Trend Analysis Forecast By Market Taxonomy, 2021-2031
13.3.1. By Country
13.3.1.1. Brazil
13.3.1.2. Mexico
13.3.1.3. Argentina
13.3.1.4. Rest of Latin America
13.3.2. By Drug Type
13.3.3. By Indication
13.3.4. By Distribution Channel
13.4. Market Attractiveness Analysis
13.5. Key Market Participants – Intensity Mapping
13.6. Drivers and Restraints – Impact Analysis
14. Europe Irritable Bowel Syndrome Treatment Market Analysis 2016-2020 and Forecast 2021-2031
14.1. Introduction
14.2. Historical Market Size (In Value or Size in US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
14.3. Current and Future Market Size (In Value or Size in US$ Mn) Trend Analysis Forecast By Market Taxonomy 2021-2031
14.3.1. By Country
14.3.1.1. Germany
14.3.1.2. Italy
14.3.1.3. France
14.3.1.4. U.K.
14.3.1.5. Spain
14.3.1.6. BENELUX
14.3.1.7. Russia
14.3.1.8. Rest of Europe
14.3.2. By Drug Type
14.3.3. By Indication
14.3.4. By Distribution Channel
14.4. Market Attractiveness Analysis
14.5. Key Market Participants – Intensity Mapping
14.6. Drivers and Restraints – Impact Analysis
15. South Asia and Pacific Irritable Bowel Syndrome Treatment Market Analysis 2016-2020 and Forecast 2021-2031
15.1. Introduction
15.2. Historical Market Size (In Value or Size in US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
15.3. Current and Future Market Size (In Value or Size in US$ Mn) Trend Analysis By Market Taxonomy, 2021-2031
15.3.1. By Country
15.3.1.1. India
15.3.1.2. Thailand
15.3.1.3. Indonesia
15.3.1.4. Malaysia
15.3.1.5. Australia and New Zealand
15.3.1.6. Rest of South Asia and Pacific
15.3.2. By Drug Type
15.3.3. By Indication
15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
15.5. Key Market Participants – Intensity Mapping
15.6. Drivers and Restraints – Impact Analysis
16. East Asia Irritable Bowel Syndrome Treatment Market Analysis 2016-2020 and Forecast 2021-2031
16.1. Introduction
16.2. Historical Market Size (In Value or Size in US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
16.3. Current and Future Market Size (In Value or Size in US$ Mn) Trend Analysis By Market Taxonomy, 2021-2031
16.3.1. By Country
16.3.1.1. China
16.3.1.2. Japan
16.3.1.3. South Korea
16.3.1.4. Rest of East Asia
16.3.2. By Drug Type
16.3.3. By Indication
16.3.4. By Distribution Channel
16.4. Market Attractiveness Analysis
16.5. Key Market Participants – Intensity Mapping
16.6. Drivers and Restraints – Impact Analysis
17. Middle East and Africa Irritable Bowel Syndrome Treatment Market Analysis 2016-2020 and Forecast 2021-2031
17.1. Introduction
17.2. Historical Market Size (In Value or Size in US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020
17.3. Current and Future Market Size (In Value or Size in US$ Mn) Trend Analysis By Market Taxonomy, 2021-2031
17.3.1. By Country
17.3.1.1. GCC Countries
17.3.1.2. Turkey
17.3.1.3. South Africa
17.3.1.4. Rest of Middle East and Africa
17.3.2. By Drug Type
17.3.3. By Indication
17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
17.5. Key Market Participants – Intensity Mapping
17.6. Drivers and Restraints – Impact Analysis
18. Key Countries Irritable Bowel Syndrome Treatment Market Analysis 2021 & 2031
18.1. U.S. Irritable Bowel Syndrome Treatment Market Value (US$) Analysis, 2021 & 2031
18.1.1. By Drug Type
18.1.2. By Indication
18.1.3. By Distribution Channel
18.2. Canada Irritable Bowel Syndrome Treatment Market Value (US$) Analysis, 2021 & 2031
18.2.1. By Drug Type
18.2.2. By Indication
18.2.3. By Distribution Channel
18.3. Brazil Irritable Bowel Syndrome Treatment Market Value (US$) Analysis, 2021 & 2031
18.3.1. By Drug Type
18.3.2. By Indication
18.3.3. By Distribution Channel
18.4. Mexico Irritable Bowel Syndrome Treatment Market Value (US$) Analysis, 2021 & 2031
18.4.1. By Drug Type
18.4.2. By Indication
18.4.3. By Distribution Channel
18.5. Argentina Irritable Bowel Syndrome Treatment Market Value (US$) Analysis, 2021 & 2031
18.5.1. By Drug Type
18.5.2. By Indication
18.5.3. By Distribution Channel
18.6. U.K. Irritable Bowel Syndrome Treatment Market Value (US$) Analysis, 2021 & 2031
18.6.1. By Drug Type
18.6.2. By Indication
18.6.3. By Distribution Channel
18.7. Germany Irritable Bowel Syndrome Treatment Market Value (US$) Analysis, 2021 & 2031
18.7.1. By Drug Type
18.7.2. By Indication
18.7.3. By Distribution Channel
18.8. France Irritable Bowel Syndrome Treatment Market Value (US$) Analysis, 2021 & 2031
18.8.1. By Drug Type
18.8.2. By Indication
18.8.3. By Distribution Channel
18.9. Italy Irritable Bowel Syndrome Treatment Market Value (US$) Analysis, 2021 & 2031
18.9.1. By Drug Type
18.9.2. By Indication
18.9.3. By Distribution Channel
18.10. Spain Irritable Bowel Syndrome Treatment Market Value (US$) Analysis, 2021 & 2031
18.10.1. By Drug Type
18.10.2. By Indication
18.10.3. By Distribution Channel
18.11. BENELUX Irritable Bowel Syndrome Treatment Market Value (US$) Analysis, 2021 & 2031
18.11.1. By Drug Type
18.11.2. By Indication
18.11.3. By Distribution Channel
18.12. Russia Irritable Bowel Syndrome Treatment Market Value (US$) Analysis, 2021 & 2031
18.12.1. By Drug Type
18.12.2. By Indication
18.12.3. By Distribution Channel
18.13. India Irritable Bowel Syndrome Treatment Market Value (US$) Analysis, 2021 & 2031
18.13.1. By Drug Type
18.13.2. By Indication
18.13.3. By Distribution Channel
18.14. Indonesia Irritable Bowel Syndrome Treatment Market Value (US$) Analysis, 2021 & 2031
18.14.1. By Drug Type
18.14.2. By Indication
18.14.3. By Distribution Channel
18.15. Malaysia Irritable Bowel Syndrome Treatment Market Value (US$) Analysis, 2021 & 2031
18.15.1. By Drug Type
18.15.2. By Indication
18.15.3. By Distribution Channel
18.16. Thailand Irritable Bowel Syndrome Treatment Market Value (US$) Analysis, 2021 & 2031
18.16.1. By Drug Type
18.16.2. By Indication
18.16.3. By Distribution Channel
18.17. Japan Irritable Bowel Syndrome Treatment Market Value (US$) Analysis, 2021 & 2031
18.17.1. By Drug Type
18.17.2. By Indication
18.17.3. By Distribution Channel
18.18. China Irritable Bowel Syndrome Treatment Market Value (US$) Analysis, 2021 & 2031
18.18.1. By Drug Type
18.18.2. By Indication
18.18.3. By Distribution Channel
18.19. South Korea Irritable Bowel Syndrome Treatment Market Value (US$) Analysis, 2021 & 2031
18.19.1. By Drug Type
18.19.2. By Indication
18.19.3. By Distribution Channel
18.20. Australia Irritable Bowel Syndrome Treatment Market Value (US$) Analysis, 2021 & 2031
18.20.1. By Drug Type
18.20.2. By Indication
18.20.3. By Distribution Channel
18.21. New Zealand Irritable Bowel Syndrome Treatment Market Value (US$) Analysis, 2021 & 2031
18.21.1. By Drug Type
18.21.2. By Indication
18.21.3. By Distribution Channel
18.22. GCC Countries Irritable Bowel Syndrome Treatment Market Value (US$) Analysis, 2021 & 2031
18.22.1. By Drug Type
18.22.2. By Indication
18.22.3. By Distribution Channel
18.23. Turkey Irritable Bowel Syndrome Treatment Market Value (US$) Analysis, 2021 & 2031
18.23.1. By Drug Type
18.23.2. By Indication
18.23.3. By Distribution Channel
18.24. South Africa Irritable Bowel Syndrome Treatment Market Value (US$) and Analysis, 2021 & 2031
18.24.1. By Drug Type
18.24.2. By Indication
18.24.3. By Distribution Channel
19. Market Structure Analysis
19.1. Market Analysis by Tier of Companies
19.2. Market Concentration
19.3. Market Share Analysis of Top Players
19.4. Market Presence Analysis
19.4.1.1. Regional footprint of Players
19.4.1.2. Method foot print by Players
19.4.1.3. Channel Foot Print by Players
20. Competition Analysis
20.1. Competition Dashboard
20.2. Competition Benchmarking
20.3. Competition Deep Dive
20.3.1. Takeda Pharmaceutical Company Limited
20.3.1.1. Overview
20.3.1.2. Product Portfolio
20.3.1.3. Profitability by Market Segments (Product/Distribution Channel/Region)
20.3.1.4. Sales Footprint
20.3.1.5. Strategy Overview
20.3.1.5.1. Marketing Strategy
20.3.1.5.2. Product Strategy
20.3.1.5.3. Distribution Channel Strategy
20.3.2. Pfizer, Inc.
20.3.2.1. Overview
20.3.2.2. Product Portfolio
20.3.2.3. Profitability by Market Segments (Product/Distribution Channel/Region)
20.3.2.4. Sales Footprint
20.3.2.5. Strategy Overview
20.3.2.5.1. Marketing Strategy
20.3.2.5.2. Product Strategy
20.3.2.5.3. Distribution Channel Strategy
20.3.3. Abbott Laboratories
20.3.3.1. Overview
20.3.3.2. Product Portfolio
20.3.3.3. Profitability by Market Segments (Product/Distribution Channel/Region)
20.3.3.4. Sales Footprint
20.3.3.5. Strategy Overview
20.3.3.5.1. Marketing Strategy
20.3.3.5.2. Product Strategy
20.3.3.5.3. Distribution Channel Strategy
20.3.4. Novartis AG
20.3.4.1. Overview
20.3.4.2. Product Portfolio
20.3.4.3. Profitability by Market Segments (Product/Distribution Channel/Region)
20.3.4.4. Sales Footprint
20.3.4.5. Strategy Overview
20.3.4.5.1. Marketing Strategy
20.3.4.5.2. Product Strategy
20.3.4.5.3. Distribution Channel Strategy
20.3.5. AstraZeneca PLC
20.3.5.1. Overview
20.3.5.2. Product Portfolio
20.3.5.3. Profitability by Market Segments (Product/Distribution Channel/Region)
20.3.5.4. Sales Footprint
20.3.5.5. Strategy Overview
20.3.5.5.1. Marketing Strategy
20.3.5.5.2. Product Strategy
20.3.5.5.3. Distribution Channel Strategy
20.3.6. Ironwood Pharmaceuticals Inc. and Allergan Plc
20.3.6.1. Overview
20.3.6.2. Product Portfolio
20.3.6.3. Profitability by Market Segments (Product/Distribution Channel/Region)
20.3.6.4. Sales Footprint
20.3.6.5. Strategy Overview
20.3.6.5.1. Marketing Strategy
20.3.6.5.2. Product Strategy
20.3.6.5.3. Distribution Channel Strategy
20.3.7. Bausch Health Companies Inc.
20.3.7.1. Overview
20.3.7.2. Product Portfolio
20.3.7.3. Profitability by Market Segments (Product/Distribution Channel/Region)
20.3.7.4. Sales Footprint
20.3.7.5. Strategy Overview
20.3.7.5.1. Marketing Strategy
20.3.7.5.2. Product Strategy
20.3.7.5.3. Distribution Channel Strategy
20.3.8. GlaxoSmithKline, Plc.
20.3.8.1. Overview
20.3.8.2. Product Portfolio
20.3.8.3. Profitability by Market Segments (Product/Distribution Channel/Region)
20.3.8.4. Sales Footprint
20.3.8.5. Strategy Overview
20.3.8.5.1. Marketing Strategy
20.3.8.5.2. Product Strategy
20.3.8.5.3. Distribution Channel Strategy
20.3.9. Lexicon Pharmaceuticals, Inc.
20.3.9.1. Overview
20.3.9.2. Product Portfolio
20.3.9.3. Profitability by Market Segments (Product/Distribution Channel/Region)
20.3.9.4. Sales Footprint
20.3.9.5. Strategy Overview
20.3.9.5.1. Marketing Strategy
20.3.9.5.2. Product Strategy
20.3.9.5.3. Distribution Channel Strategy
20.3.10. Sucampo Pharmaceuticals, Inc.
20.3.10.1. Overview
20.3.10.2. Product Portfolio
20.3.10.3. Profitability by Market Segments (Product/Distribution Channel/Region)
20.3.10.4. Sales Footprint
20.3.10.5. Strategy Overview
20.3.10.5.1. Marketing Strategy
20.3.10.5.2. Product Strategy
20.3.10.5.3. Distribution Channel Strategy
21. Assumptions and Acronyms Used
22. Research Methodology